Kim Hodgson, MD is the David Sumner endowed Chair of vascular and endovascular surgery at Southern Illinois University School of Medicine in Springfield, Ill. and is the current president of the Society for Vascular Surgery.  He received his medical degree at the University of Pennsylvania, did his general surgery residency at Albany medical college and vascular surgery fellowship at the Southern Illinois University. He has over 100 peer-reviewed publications, 40 book chapters and has been the PI on numerous clinical trials.  He was the inaugural editor of VESAP and co-editor in chief of the second and third editions of VESAP. Dr. Hodgson served on the Vascular Surgery Board and recently presented as the SVS representative at the multidisciplinary panel for the Circulatory system devices and medical devices advisory committee as part of the FDA oversight into paclitaxel devices in PAD.

These are the opinions of Dr. Hodgson and do not necessarily represent a formal stance by the SVS. 

Updates from The FDA Circulatory System Devices Panel Meeting, June 19-20th, 2019:

• US FDA Panel Reviews Paclitaxel Device Data: No Recommendations Issued as More Work is Needed. VascularNews.com. June 20, 2019.
• FDA Letter to Health Care Providers, UPDATE: Treatment of Peripheral Arterial Disease with Paclitaxel-Coated Balloons and Paclitaxel-Eluting Stents Potentially Associated with Increased Mortality. FDA.gov. June 20, 2019.
• FDA Executive Summary, Circulatory System Devices Panel Meeting, Paclitaxel-Coated Balloon and Paclitaxel-Eluting Stent Late Mortality Panel, June 19-20, 2019

Next steps:

• Society for Vascular Surgery’s VQI Adds New Analysis to Paclitaxel Device Discussion. VascularNews.com. June 14, 2019.
• The problems with Target Lesion Revascularization (TLR) as an endpoint. Vascular Specialist. January 25, 2015.

Support Audible Bleeding!